Pacific Edge Limited is a cancer diagnostics company developing and commercialising tests for the early detection and management of cancer.
Established in 2001, Pacific Edge combines state of the art molecular biology, gene expression analysis and signature development and validation with world-class tissue banks and clinical data. These combined skills and capabilities, along with proprietary analytical software, have enabled us to identify unique gene and protein signatures for the development of better cancer management tools.
Our commercial objectives are to discover, develop and commercialise new, simple-to-use genomic and proteomic tools for the earlier detection, improved characterisation and better management of a range of cancers. Commercial products developed by Pacific Edge consist of genomic and proteomic tests developed for use in clinical and point of care applications.
Pacific Edge's genetic databases are the discovery engine for diagnostic biomarkers. Genes, as candidate biomarkers, are identified when they are differentially expressed in normal tissue compared with tumour tissue. Pacific Edge focuses on the development of biomarkers from RNA and protein antigens.
Visit Pacific Edge to find out more about our company, our partners, and our other products.
Lab bench at Pacific Edge